Anti-IL-6 antibody
Inventors
Chen, Yan • Gardner, Debra • Knight, David M. • Lark, Michael W. • Liang, Bailin • Marquis, David M. • Shealy, David J. • Smith, Eric Michael • Song, Xiao-yu R. • Stojanovic-Susulic, Vedrana • Sweet, Raymond • Tam, Susan • Vasserot, Alain P. • Wu, Sheng-Jiun • Yang, Jing
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12065488-B2
Publication Date
2024-08-20
Expiration Date
Abstract
Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
Core Innovation
The invention relates to an article of manufacture for human pharmaceutical or diagnostic use that comprises packaging material and a container holding a solution or a lyophilized form of an IL-6 antibody. The IL-6 antibody comprises a light chain variable region and a heavy chain variable region, and the light chain variable region is defined by complementarity determining region light chain sequences CDRL1, CDRL2, and CDRL3, while the heavy chain variable region is defined by complementarity determining region heavy chain sequences CDRH1, CDRH2, and CDRH3.
The complementarity determining region sequences are specified using SEQ ID NOs, including SEQ ID NO:132, 133, and 134 for the light chain CDRs, and SEQ ID NO:135, 136, and 137 for the heavy chain CDRs. For the light chain CDRs and heavy chain CDRs, specific amino acid sequence patterns are defined with position-specific residue constraints expressed with X positions constrained to particular amino acids.
The disclosed concept is directed to anti-IL-6 therapy and/or IL-6-related diagnostic use, emphasizing a human IL-6 antibody format with defined CDR composition.
Claims Coverage
The consolidated claim coverage includes one independent claim directed to an article of manufacture for human pharmaceutical or diagnostic use. The inventive features center on a container holding a solution or a lyophilized IL-6 antibody and on defined light- and heavy-chain variable region CDR amino acid sequences using SEQ ID NOs and position-specific residue constraints; in total, six CDR-defined regions are specified.
Packaged container for human IL-6 antibody in solution or lyophilized form
An article of manufacture for human pharmaceutical or diagnostic use comprising packaging material and a container comprising a solution or a lyophilized form of an IL-6 antibody, where the antibody comprises a light chain variable region and a heavy chain variable region.
Light-chain variable region defined by CDRL1, CDRL2, and CDRL3 sequence constraints
The light chain variable region comprises a CDRL1 amino acid sequence of SEQ ID NO:132 with a sequence pattern of S-X1-X2-X3-X4-V-X5-Y-M-Y under defined X1–X5 residue constraints; a CDRL2 amino acid sequence of SEQ ID NO:133 with a D-X6-S-X7-L-X8-S pattern under defined X6–X8 residue constraints; and a CDRL3 amino acid sequence of SEQ ID NO:134 with a X9-X10-W-S-G-Y-P-Y-T pattern under defined X9–X10 residue constraints.
Heavy-chain variable region defined by CDRH1, CDRH2, and CDRH3 sequence constraints
The heavy chain variable region comprises a CDRH1 amino acid sequence of SEQ ID NO:135 with a G-F-X11-X12-S-X13-F-A-X14-S pattern under defined X11–X14 residue constraints; a CDRH2 amino acid sequence of SEQ ID NO:136 with a K-X15-S-X16-G-G-S-X17-X18-Y-X19-X20-D-T-X21-X22-X23 pattern under defined X15–X23 residue constraints; and a CDRH3 amino acid sequence of SEQ ID NO:137 with a Q-L-W-G-X24-Y-A-L-D-X25 pattern under defined X24–X25 residue constraints.
Coverage is focused on a human pharmaceutical or diagnostic packaged article where the container holds a solution or lyophilized IL-6 antibody. The antibody is structurally defined by explicit light- and heavy-chain variable-region CDR amino acid sequences using SEQ ID NOs and constrained residue patterns.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?